Eli Lilly and Company (NYSE:LLY) Shares Down 0.1%

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares were down 0.1% during mid-day trading on Thursday . The stock traded as low as $745.69 and last traded at $750.04. Approximately 421,050 shares traded hands during trading, a decline of 86% from the average daily volume of 3,049,915 shares. The stock had previously closed at $750.77.

Analysts Set New Price Targets

Several equities research analysts have issued reports on LLY shares. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 7th. Bank of America upped their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a "buy" rating in a research note on Friday, March 1st. TheStreet upgraded shares of Eli Lilly and Company from a "c+" rating to a "b" rating in a research note on Friday, March 8th. Truist Financial restated a "buy" rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Finally, Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a research note on Tuesday, April 2nd. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $728.05.

Eli Lilly and Company Stock Down 0.6 %

The company has a market capitalization of $708.77 billion, a price-to-earnings ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. The stock's fifty day simple moving average is $764.03 and its two-hundred day simple moving average is $657.67. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analysts' expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm's revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.09 earnings per share. On average, sell-side analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares of the company's stock, valued at $64,177,109,911.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of the business. Dash Acquisitions Inc. increased its holdings in shares of Eli Lilly and Company by 12.3% in the 1st quarter. Dash Acquisitions Inc. now owns 373 shares of the company's stock worth $280,000 after acquiring an additional 41 shares during the period. Capital Advisors Ltd. LLC increased its holdings in shares of Eli Lilly and Company by 1.1% in the 1st quarter. Capital Advisors Ltd. LLC now owns 1,362 shares of the company's stock worth $1,059,000 after acquiring an additional 15 shares during the period. Woodmont Investment Counsel LLC increased its holdings in shares of Eli Lilly and Company by 1.6% in the 1st quarter. Woodmont Investment Counsel LLC now owns 4,835 shares of the company's stock worth $3,761,000 after acquiring an additional 74 shares during the period. Exchange Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 19.1% in the 1st quarter. Exchange Capital Management Inc. now owns 1,995 shares of the company's stock worth $1,552,000 after acquiring an additional 320 shares during the period. Finally, Leonard Rickey Investment Advisors P.L.L.C. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $243,000. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.